Creative Biolabs launches expanded iPSC and astrocyte differentiation services to support next‑generation disease modeling and neurobiology research.
— As stem‑cell–based systems continue to gain traction as more predictive alternatives to traditional animal and immortalized cell models, researchers are increasingly turning to induced pluripotent stem cells (iPSCs) to capture patient‑specific biology and improve translational relevance. Creative Biolabs has introduced a comprehensive of services to support disease models and neuroscience research.
With the stem‑cell and neurobiology platforms, Creative Biolabs provides researchers with customizable, scalable, and quality‑controlled solutions for generating human‑relevant cell types. The services target key bottlenecks in translational research, including variability in primary cell sourcing, inconsistent differentiation outcomes, and limited access to mature glial models.
“The expansion of our iPSC and neuroglial differentiation capabilities reflects our commitment to enabling more physiologically relevant research systems,” said the Director of stem cell innovation at Creative Biolabs. “By integrating reprogramming, lineage‑specific differentiation, and specialized astrocyte production, we aim to give scientists a reliable starting point for developing next‑generation therapeutics.”
Creative Biolabs’ iPSC reprogramming services include viral, episomal, mRNA, and protein‑based delivery systems optimized for high efficiency and minimal genomic footprint. The platform supports end‑to‑end workflows—from somatic cell sourcing to clone expansion and pluripotency validation—ensuring stable, high‑quality iPSC lines suitable for downstream differentiation and gene‑editing applications.
The company’s iPSC differentiation services span neuronal, cardiomyocyte, hepatocyte, ocular, hematopoietic, and osteogenic lineages. Compared with traditional induction methods, Creative Biolabs’ optimized protocols offer improved reproducibility, higher purity, and flexible induction strategies such as small‑molecule modulation, growth‑factor guidance, and rapid NGN2‑driven neuronal conversion. These features help address common challenges in disease modeling, functional screening, and toxicity assessment.
Complementing these capabilities, the astrocyte differentiation service—powered by the STEMOD neuroscience platform—provides highly pure, functionally mature astrocytes derived from neural progenitor intermediates. These astrocytes exhibit defined maturity states and robust physiological properties, supporting research in neurodegeneration, neuroinflammation, synaptic regulation, and blood–brain barrier biology.
A biotechnology client who recently adopted the platform commented: “The consistency of Creative Biolabs’ iPSC‑derived astrocytes has significantly improved our neuroinflammation assays. The reproducibility alone has shortened our screening cycles,” said a CNS Research at a U.S.‑based biotech company.
Learn more, please visit https://www.creative-biolabs.com/stem-cell-therapy/.
About Creative Biolabs
Creative Biolabs, a global provider of advanced cell‑engineering and translational research solutions committed to accelerating biomedical innovation, expands its iPSC and astrocyte platforms to deliver scalable, reproducible human‑relevant disease models.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Address: Shirley, NY 11967, USA
Phone: 6318306441
Website: https://www.creative-biolabs.com/stem-cell-therapy/
Release ID: 89184523
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.